Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T-cells

Therapeutic ex vivo T-cell expansion is limited by low rates and T-cell products of limited functionality. Here we describe a system that mimics natural antigen-presenting cells (APCs) and consists of a fluid lipid bilayer supported by mesoporous silica micro-rods. The lipid bilayer presents membrane-bound cues for T-cell receptor stimulation and costimulation, while the micro-rods enable sustained release of soluble paracrine cues. Using anti-CD3, anti-CD28, and interleukin-2, we show that the APC-mimetic scaffolds (APC-ms) promote two- to tenfold greater polyclonal expansion of primary mouse and human T cells compared with commercial expansion beads (Dynabeads). The efficiency of expansion depends on the density of stimulatory cues and the amount of material in the starting culture. Following a single stimulation, APC-ms enables antigen-specific expansion of rare cytotoxic T-cell subpopulations at a greater magnitude than autologous monocyte-derived dendritic cells after 2 weeks. APC-ms support over fivefold greater expansion of restimulated CD19 CAR-T cells than Dynabeads, with similar efficacy in a xenograft lymphoma model.

[1]  J. Gartner,et al.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. , 2015, The Journal of clinical investigation.

[2]  W. Schamel,et al.  Full activation of the T cell receptor requires both clustering and conformational changes at CD3. , 2007, Immunity.

[3]  Mark M. Davis,et al.  T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.

[4]  R. O'Reilly,et al.  Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy , 2015, Advancements in genetic engineering.

[5]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[6]  T. Schumacher,et al.  CD27 is required for generation and long-term maintenance of T cell immunity , 2000, Nature Immunology.

[7]  Ton N. Schumacher,et al.  Adoptive cellular therapy: A race to the finish line , 2015, Science Translational Medicine.

[8]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[9]  Marcus D. Collins,et al.  Tuning lipid mixtures to induce or suppress domain formation across leaflets of unsupported asymmetric bilayers , 2008, Proceedings of the National Academy of Sciences.

[10]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[11]  Youngjin Choi,et al.  Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.

[12]  Tarek R. Fadel,et al.  A carbon nanotube-polymer composite for T-cell therapy. , 2014, Nature nanotechnology.

[13]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[14]  I. Szleifer,et al.  Stability and liquid-liquid phase separation in mixed saturated lipid bilayers. , 2009, Biophysical journal.

[15]  Arup K Chakraborty,et al.  The Immunological Synapse Balances T Cell Receptor Signaling and Degradation , 2003, Science.

[16]  Tarek R. Fadel,et al.  Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. , 2008, Nano letters.

[17]  Kwangmeyung Kim,et al.  Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. , 2012, Angewandte Chemie.

[18]  I. Gustafson,et al.  Planar lipid bilayers on solid supports from liposomes--factors of importance for kinetics and stability. , 1997, Biochimica et biophysica acta.

[19]  J Christopher Love,et al.  Functional single-cell analysis of T-cell activation by supported lipid bilayer-tethered ligands on arrays of nanowells. , 2012, Lab on a chip.

[20]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[21]  J. Stephenson,et al.  Characterization and control of lipid layer fluidity in hybrid bilayer membranes. , 2007, Journal of the American Chemical Society.

[22]  Jonathan P Schneck,et al.  Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. , 2014, Biomaterials.

[23]  J. Mcclendon.  “Race” to the Finish Line , 2017 .

[24]  R. Kurlander,et al.  Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation , 2010, Journal of Translational Medicine.

[25]  T. Fahmy,et al.  A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  D. Irvine,et al.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. , 2011, Biomaterials.

[27]  Michel Sadelain,et al.  Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.

[28]  C. Figdor,et al.  Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells , 2014, Trends in biotechnology.

[29]  Youngjin Choi,et al.  The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration. , 2016, Biomaterials.

[30]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[31]  Joe-Marc Chauvin,et al.  HLA Anchor Optimization of the Melan-A–HLA-A2 Epitope within a Long Peptide Is Required for Efficient Cross-Priming of Human Tumor-Reactive T Cells , 2012, The Journal of Immunology.

[32]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[33]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[34]  J. Sunshine,et al.  Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. , 2015, Small.

[35]  Thomas Stockner,et al.  Membrane-mediated effect on ion channels induced by the anesthetic drug ketamine. , 2010, Journal of the American Chemical Society.

[36]  J. Friedberg,et al.  Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1 , 2016 .

[37]  O. Eremin,et al.  Dendritic cells are dysfunctional in patients with operable breast cancer , 2004, Cancer Immunology, Immunotherapy.

[38]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[39]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[40]  Tarek R. Fadel,et al.  An Artificial Antigen-presenting Cell with Paracrine Delivery of IL-2 Impacts the Magnitude and Direction of the T Cell Response* , 2011, The Journal of Biological Chemistry.

[41]  K. Kinzler,et al.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. , 2015, ACS nano.

[42]  C. Figdor,et al.  Polymer-based synthetic dendritic cells for tailoring robust and multifunctional T cell responses. , 2015, ACS chemical biology.

[43]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[44]  C. Reich,et al.  Asymmetric structural features in single supported lipid bilayers containing cholesterol and GM1 resolved with synchrotron X-Ray reflectivity. , 2008, Biophysical journal.

[45]  S. Albani,et al.  The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells , 2008, Haematologica.

[46]  P. Greenberg,et al.  Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells , 2014, Nature Protocols.

[47]  C. Turtle,et al.  Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy , 2010, Cancer journal.

[48]  Ton N. Schumacher,et al.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.

[49]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[50]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[51]  B. Alarcón,et al.  The immunological synapse: a cause or consequence of T‐cell receptor triggering? , 2011, Immunology.

[52]  M. Essand,et al.  Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors , 2014, Molecular therapy. Methods & clinical development.

[53]  A. Mackensen,et al.  Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. , 2006, Journal of Clinical Oncology.

[54]  Neel S. Joshi,et al.  Versatile click alginate hydrogels crosslinked via tetrazine-norbornene chemistry. , 2015, Biomaterials.